22 §8737. Rulemaking
§8737. Rulemaking The organization may adopt rules to implement this subchapter. Rules adopted pursuant to this section are major substantive rules as defined in Title 5, chapter 375, subchapter 2‑A. [PL 2019, c. 470, §8 (NEW).] SECTION HISTORY PL 2019, c. 470, §8 (NEW).
22 §8741. International referenced rate pricing
§8741. International referenced rate pricing 1. Definitions. As used in this section, unless the context otherwise indicates, the following terms have the following meanings. A. “Manufacturer” has the same meaning as in section 8731, subsection 3. [PL 2021, c. 606, §1 (NEW).] B. “Prescription drug” has the same meaning as in section 8731, […]
22 §8719. Provider database and service locator tool
§8719. Provider database and service locator tool 1. Provider database. The organization shall develop and maintain a multipayor provider database that must be used by the department to provide information for a service locator available on a publicly accessible website for use by the public, by providers and by state agencies in accordance with this […]
22 §8731. Definitions
§8731. Definitions As used in this subchapter, unless the context otherwise indicates, the following terms have the following meanings. [PL 2019, c. 470, §8 (NEW).] 1. Brand-name drug. “Brand-name drug” means a prescription drug marketed under a proprietary name or registered trademark name, including a biological product. [PL 2019, c. 470, §8 (NEW).] […]
22 §8732. Drug price notifications and disclosures
§8732. Drug price notifications and disclosures 1. Notifications by manufacturers. [PL 2021, c. 305, §4 (AMD); MRSA T. 22 §8732, sub-§1 (RP).] 1-A. Public notice of substantial drug price change or introduction. No later than January 30, 2022 and annually thereafter, the organization shall produce and post on its publicly accessible website a list of […]
22 §8708. Clinical data
§8708. Clinical data Clinical data must be filed, stored and managed as follows. [PL 1995, c. 653, Pt. A, §2 (NEW); PL 1995, c. 653, Pt. A, §7 (AFF).] 1. Information required. Pursuant to rules adopted by the board for form, medium, content and time for filing, each health care facility shall file with […]
22 §8733. Confidentiality
§8733. Confidentiality Information provided to the organization as required by this subchapter by a manufacturer, wholesale drug distributor or pharmacy benefits manager is confidential and not a public record under Title 1, chapter 13, except that the organization may share information: [PL 2019, c. 470, §8 (NEW).] 1. Bureau of Insurance. With the Department […]
22 §8708-A. Quality data
§8708-A. Quality data The board shall adopt rules regarding the collection of quality data. The board shall work with the Maine Quality Forum and the Maine Quality Forum Advisory Council established in Title 24‑A, chapter 87, subchapter 2 to develop the rules. The rules must be based on the quality measures adopted by the Maine […]
22 §8734. Registration requirements
§8734. Registration requirements Beginning January 1, 2020, manufacturers, wholesale drug distributors and pharmacy benefits managers subject to this subchapter shall register annually with the organization in a manner prescribed by the organization. [PL 2021, c. 305, §8 (AMD).] SECTION HISTORY PL 2019, c. 470, §8 (NEW). PL 2021, c. 305, §8 (AMD).
22 §8709. Financial data; scope of service data
§8709. Financial data; scope of service data Financial data and scope of service data must be filed, stored and managed as follows. [PL 1999, c. 353, §15 (AMD).] 1. Financial data. Each health care facility shall file with the organization, in a form specified by rule pursuant to section 8704, financial information including costs […]